Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $315.6 million.

  • Veracyte's Cash & Equivalents rose 1513.94% to $315.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $315.6 million, marking a year-over-year increase of 1513.94%. This contributed to the annual value of $239.1 million for FY2024, which is 1045.63% up from last year.
  • Latest data reveals that Veracyte reported Cash & Equivalents of $315.6 million as of Q3 2025, which was up 1513.94% from $219.5 million recorded in Q2 2025.
  • Over the past 5 years, Veracyte's Cash & Equivalents peaked at $327.5 million during Q2 2021, and registered a low of $153.4 million during Q2 2022.
  • In the last 5 years, Veracyte's Cash & Equivalents had a median value of $202.5 million in 2023 and averaged $215.7 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 12213.97% in 2021, then plummeted by 5315.24% in 2022.
  • Quarter analysis of 5 years shows Veracyte's Cash & Equivalents stood at $173.2 million in 2021, then dropped by 10.94% to $154.2 million in 2022, then surged by 40.33% to $216.5 million in 2023, then increased by 10.46% to $239.1 million in 2024, then skyrocketed by 31.99% to $315.6 million in 2025.
  • Its Cash & Equivalents stands at $315.6 million for Q3 2025, versus $219.5 million for Q2 2025 and $186.1 million for Q1 2025.